Sage Therapeutics SURVEYOR-HD study endorsed* by EHDN

Study aims and goal: The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington’s Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance and the effect of SAGE-718 on cognitive performance and functioning in participants with HD. No. of study participants […]

Weiterlesen…

SOM Innovation Biotech European Study endorsed* by EHDN

Study aims and goal: Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington’s Disease with choreic movements. No. of study participants and sites: This Phase IIb study aims to recruit participants from 22 sites in France, Germany, Italy, Poland, Spain, […]

Weiterlesen…

Joint working Genetic Modifiers Working Group, Genetic Counseling & Testing Working Group and Incidental Findings Task Force meeting

Meeting notice: Joint working Genetic Modifiers Working Group, Genetic Counseling & Testing Working Group and Incidental Findings Task Force meeting Thursday 15th September 2022, 13.00 – 17.00 Location: room Magenta B, Bologna Congressi S.r.l (if you would like information about joining remotely please let us know) Application of genetic modifier of Huntington’s disease data in […]

Weiterlesen…